20 Jan 2014, BioSpectrum Bureau , BioSpectrum
Singapore: Australian biopharmaceutical company Imugene has appointed Dr Christoph Zielinski and Dr Ursula Wiedermann to the company's scientific advisory board.
"We are extremely pleased that two scientists of such substantial international calibre, Professors Zielinski and Wiedermann, have joined the Imugene Scientific Advisory Board. They are both internationally recognized as leaders in oncology, vaccinology and immunology. Together with their colleagues, both have been instrumental in the advancement of Imugene's immunotherapy candidate HER-Vaxx," said Dr Nick Ede, executive director, Imugene.
Professor Zielinski is director of the clinical division of oncology and chairman of the department of medicine at the Medical University of Vienna, Austria. He serves as coordinator of the comprehensive cancer center at the Medical University of Vienna and the General Hospital in Vienna, Austria, and is president of the Central European Cooperative Oncology Group.
Professor Wiedermann is Professor of Vaccinology and Head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University Vienna. Currently she also has an appointment as Visiting Professor at the University in Göteborg, Sweden.